Literature DB >> 23143763

Molecular genetic analysis of bilateral ovarian germ cell tumors.

E Hennes1, S Zahn, L F Lopes, S Schönberger, I Leuschner, U Göbel, G Calaminus, D T Schneider.   

Abstract

BACKGROUND: Ovarian germ cell tumors (oGCTs) are rare and highly heterogeneous with regard to their clinical and histologic appearance. The risk of tumor development is higher in children with aberrant sexual differentiation. Development of gonadoblastomas is seen in young women with 46,XY gonadal dysgenesis. At least 50 % of gonadoblastomas may develop into malignant oGCTs, mostly dysgerminomas. In this study, we evaluated bilateral oGCTs in clinically inapparent patients for sex chromosomal aberrations. PATIENTS AND METHODS: We analyzed tumor samples of 15 patients with synchronous bilateral oGCTs enrolled onto the consecutive MAKEI trials for non-testicular GCTs. Paraffin embedded samples from the Kiel German Childhood Tumor Registry were evaluated for the presence of Y-chromosomal sequences. Molecular genetic techniques included comparative genomic hybridization, polymerase chain reaction, and fluorescence in situ hybridization.
RESULTS: Among 15 patients with bilateral oGCTs, Y-chromosomal DNA sequences were detected in 6 tumors. Both mature teratomas were negative for Y-chromosomal DNA. Thus, 5 of 12 malignant oGCTs and 1 immature teratoma (with elevated AFP) showed Y-chromosomal material. A 45(X,0) karyotype could not be demonstrated.
CONCLUSIONS: These investigations provide additional insight into the development of oGCTs: mature teratomas, which develop from postmeiotic germ cells, are not associated with gonadal dysgenesis. Bilateral immature teratomas, dysgerminomas and mixed malignant oGCTs may frequently show Y-chromosomal DNA, indicating underlying but clinically inapparent gonadal dysgenesis. Thus, the presence of aberrant Y-chromosomal sequences appears to be involved in tumor development in about half of these patients. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2012        PMID: 23143763     DOI: 10.1055/s-0032-1327606

Source DB:  PubMed          Journal:  Klin Padiatr        ISSN: 0300-8630            Impact factor:   1.349


  4 in total

1.  Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study.

Authors:  Bryan J Dicken; Deborah F Billmire; Mark Krailo; Caihong Xia; Furqan Shaikh; John W Cullen; Thomas A Olson; Farzana Pashankar; Marcio H Malogolowkin; James F Amatruda; Frederick J Rescorla; Rachel A Egler; Jonathan H Ross; Carlos Rodriguez-Galindo; A Lindsay Frazier
Journal:  Pediatr Blood Cancer       Date:  2017-12-29       Impact factor: 3.167

Review 2.  46, XY disorder of sex development (DSD) complicated by a serous borderline tumor of the ovary: a case report and review of the literature.

Authors:  Jiangying Zhao; Jiao Peng; Sisi He; Jia Yang; Xiaojun Pang
Journal:  Diagn Pathol       Date:  2020-07-23       Impact factor: 2.644

3.  Gene expression profiling of ovarian carcinomas and prognostic analysis of outcome.

Authors:  Sheng-Yun Cai; Tian Yang; Yu Chen; Jing-Wen Wang; Li Li; Ming-Juan Xu
Journal:  J Ovarian Res       Date:  2015-07-31       Impact factor: 4.234

4.  Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology.

Authors:  Gabriele Calaminus; Dominik T Schneider; Dietrich von Schweinitz; Heribert Jürgens; Nacera Infed; Stefan Schönberger; Thomas A Olson; Peter Albers; Christian Vokuhl; Raimund Stein; Leendert Looijenga; Jalid Sehouli; Martin Metzelder; Alexander Claviez; Michael Dworzak; Angelika Eggert; Birgit Fröhlich; Nicolas U Gerber; Christian P Kratz; Jörg Faber; Thomas Klingebiel; Dieter Harms; Ulrich Göbel
Journal:  Cancers (Basel)       Date:  2020-03-06       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.